Skip to main content

Advertisement

SpringerLink
Log in

Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: To assess the efficacy and safety of a novel long-acting im testosterone undecanoate (TU) formulation in comparison with testosterone enanthate (TE). Subjects and methods: An open-label, randomized, prospective clinical trial in 40 hypogonadal men (baseline serum testosterone levels <5 nmol/l), randomly assigned to 250 mg TE/3 weeks (no.=20) or 1000 mg TU im every 6 to 9 weeks for 30 weeks (no.=20). Subsequently, 32/40 men continued the study for another 114 weeks, now receiving TU 1000 mg/12 weeks. Results: TU and TE produced no statistically significant improvements in grip strength over the first 30 weeks, which only occurred after approximately 90 weeks when all subjects received TU. There were no changes in body mass index with TU and TE, neither in the follow-up period when all patients received TU. But ratios of waist to hip circumferences declined in the longer term. Total serum cholesterol, LDL cholesterol, and triglycerides declined over the first 30 weeks, while plasma HDL also declined. Plasma LDL decreased further under long-term TU therapy, while HDL then increased. Hemoglobin and hematocrit values significantly increased over the first 30 weeks in both treatment groups and then no further increase was observed. Levels did not exceed the upper limit of normal. In both treatment groups, serum prostate specific antigen levels rose slightly after 30 weeks, with no further increase over the first 12 months, remaining stable within the normal range. Plasma T before the following TU injection was above the lower limit of reference values. Four injections per year are adequate. Conclusions: Administration of TU every 12 weeks is at least as safe and efficacious for treatment of hypogonadal men as TE, with a substantially lower frequency of administration. Follow-up over 114 weeks, when all subjects received TU, showed an excellent profile of efficacy and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004, 64: 1861–91.

    Article  CAS  PubMed  Google Scholar 

  2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26: 833–76.

    Article  CAS  PubMed  Google Scholar 

  3. Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004, 10: 409–19.

    Article  CAS  PubMed  Google Scholar 

  4. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65: 275–81.

    Article  CAS  Google Scholar 

  5. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, editors. Testosterone, Action, Deficiency, Substitution. Cambridge: Cambridge University Press. 2004, 405–44.

    Google Scholar 

  6. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004, 89: 5429–34.

    Article  CAS  PubMed  Google Scholar 

  7. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005, 6: 1751–9.

    Article  CAS  PubMed  Google Scholar 

  8. Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999, 140: 414–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154: 899–906.

    Article  CAS  PubMed  Google Scholar 

  10. Rebuffe-Scrive M, Mårin P, Björntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991, 15: 791–5.

    CAS  PubMed  Google Scholar 

  11. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005, 174: 827–34.

    Article  CAS  PubMed  Google Scholar 

  12. Jockenhövel F, Blum WF, Vogel E, et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 2510–3.

    Article  PubMed  Google Scholar 

  13. Blum WF, Englaro P, Hanitsch S, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997, 82: 2904–10.

    CAS  PubMed  Google Scholar 

  14. Elbers JM, Asscheman H, Seidell JC, Frölich M, Meinders AE, Gooren LJ. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 1997, 82: 3267–70.

    CAS  PubMed  Google Scholar 

  15. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003, 24: 313–40.

    Article  CAS  PubMed  Google Scholar 

  16. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001, 111: 261–9.

    Article  CAS  PubMed  Google Scholar 

  17. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003, 24: 183–217.

    Article  CAS  PubMed  Google Scholar 

  18. Morley JE, Perry HM 3rd, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993, 41: 149–52.

    CAS  PubMed  Google Scholar 

  19. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82: 1661–7.

    Article  CAS  PubMed  Google Scholar 

  20. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85: 2670–7.

    CAS  PubMed  Google Scholar 

  21. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89: 2085–98.

    Article  CAS  PubMed  Google Scholar 

  22. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75: 1092–8.

    CAS  PubMed  Google Scholar 

  23. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997, 2: 293–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic and Outpatient Department of Internal Medicine, Univerity Clinic, Cologne

    T. Minnemann, M. Schubert, S. Freude, I. Gouni-Berthold, C. Schumann, A. Christoph & W. Krone

  2. Jenapharm Ltd & Co. KG, Jena

    D. Hübler, M. Oettel, M. Ernst & U. Mellinger

  3. Christian Hospital Herne, Herne, Germany

    F. Jockenhövel MD

Authors
  1. T. Minnemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Freude
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Hübler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Gouni-Berthold
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Schumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Christoph
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Oettel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Ernst
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. U. Mellinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. W. Krone
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Jockenhövel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Jockenhövel MD.

Additional information

These authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minnemann, T., Schubert, M., Freude, S. et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 31, 718–723 (2008). https://doi.org/10.1007/BF03346421

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346421

Key-words

Search

Navigation